Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Aug 06, 2019
Liberty Global forms possible double top at $28

Liberty Global forms possible double top at $28

Liberty Global (Nasdaq: LBTYK) is a provider of video, broadband internet, mobile telephone, and land-line telephone services to European customers. The company was founded in 2004 and is based in London, England.

The company has been struggling in recent years with the company losing money and sales declining. The company is scheduled to report earnings again on August 8 and analysts expect the company to report a loss of $0.04. Over the last three years, sales for the Liberty Global have declined at a rate of 19% per year. Sales were down by 6% in the most recent quarterly report and they are expected to decline by 23% in the upcoming report.

There are other fundamental factors that reflect the hard time the company has been having as well. The return on equity is a -7.4% and the profit margin is a paltry 1.4%. The company is also saddled with a great deal of long-term debt.

In addition to the poor fundamentals, the technical picture for Liberty Global is pointing toward a rough patch for the stock. We see on the weekly chart that the stock found support at the $28 level on numerous occasions in 2016 and 2017. The stock dipped below the price several times, but never closed out a week below it.

The stock eventually fell below $28 in the second quarter of 2018 and would eventually fall below $20. The stock rallied back in the first quarter of 2019, but it ran in to resistance at the $28 level and dropped back to $24. It rallied back up to $28 last month, but once again stalled at that price. Now it looks as if the stock has formed a double-top formation. For this pattern to be confirmed the stock will need to fall back below $24 and if it does that, there is a good chance it drops back down to $20.

What is really surprising about the overall picture for Liberty Global is that the sentiment is still somewhat optimistic. There are 13 analysts following the company and 10 of the 13 have the stock rated as a “buy”. The overall buy percentage is at 76.9%. The average buy percentage ranges between 65% and 75%. Given the decline in sales and seeing the company lose money, it is surprising to see a buy percentage that is above average.

The short interest ratio for the stock is at 4.34 currently and that is slightly higher than average. The ratio jumped from the end of June through mid-July as the number of shares sold short jumped from 6.8 million shares to 8.8 million shares. As the number of shares sold short was jumping, the average daily trading volume dropped from 2.5 million shares per day to 2 million shares per day. Meaning the numerator increased while the denominator declined—thus the big jump in the short interest ratio. The jump does indicate an increase in bearish sentiment.

Overall we see that the fundamentals aren’t looking so good, the technical picture looks bearish, and the sentiment is mixed. This will make it difficult for the stock to move higher in the coming months.

Related Ticker: LBTTX

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


Industry description

The fund seeks to achieve its investment objective by investing in an unaffiliated ETF that tracks the S&P 500 Index such as the SPDR® S&P 500 ETF Trust (SPY) when, based on technical research and analysis, the fund's adviser believes the stock market is likely to rise, and selling the ETF, and investing in an unaffiliated money market fund when the adviser believes the stock market is likely to decline.
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category LargeBlend

Profile
Details
Category
Large Blend
Address
Northern Lights Fund Trust IV
Phone
(402) 895-1600
Web
N/A
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.